Somatostatins

Product #

Description

Biochem/physiol Actions

Add to Cart

B4310 BIM 23056 ≥95% (HPLC), solid Selective sst5 somatostatin receptor antagonist.
C4801 Cyclo(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl]) ≥95% (HPLC), powder Somatostatin antagonist.
C2490 CYN 154806 trifluoroacetate salt ≥98% (HPLC) Potent and selective sst2 somatostatin receptor antagonist.
SML0132 Lanreotide acetate ≥98% (HPLC) Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.
SML0354 Neuronostatin trifluoroacetate salt ≥95% (HPLC) Neuronostatin is a peptide hormone encoded by somatostatin gene that is involved in regulation of neuronal function, blood pressure, food intake and drinking behavior. Data indicates that neuronostatin regulates cardiac contractile function and cardiomyocyte survival. Also neuronostatin significantly inhibited both food and water intake when administered centrally in adult male rats.
O1014 Octreotide ≥98% (HPLC) Octreotide is three times more potent than the native hormone in inhibiting the secretion of growth hormone glucagon and insulin in vivo. Octreotide regulates serum prolactin levels and resolves galactorrhea or (secondary) amenorrhea in acromegaly patients. Hence, this peptide can be considered as a potent therapeutic for acromegaly treatment.
Somatostatin analog that is 3-times more potent than the native hormone in inhibiting the secretion of growth hormone.
S9129 Somatostatin ≥97% (HPLC), powder Somatostatin regulates the secretion of hormones and bioactive peptides. It acts as an inhibitor in the digestive tract by inhibiting gastrin release. In the pancreatic islets, it inhibits glucagon and insulin release. Somatostatin and its synthetic analogs have been used in the treatment of neuroendocrine tumors.
S1763 Somatostatin powder, BioReagent, suitable for cell culture Somatostatin regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones.
S0885 Somatostatin powder, γ-irradiated, BioXtra, suitable for cell culture Somatostatin regulates endocrine function and cell proliferation via interaction with G-protein-coupled somatostatin receptors. It exists in two active forms produced by alternative cleavage of a single preproprotein (14 aa and 28 aa forms). Somatosatin inhibits the release of growth hormone; thyroid-stimulating hormone and a range of gastrointestinal hormones: Cholecystokinin (CCK); Enteroglucagon; Gastrin; Gastric inhibitory polypeptide (GIP); Motilin; Secretin; Vasoactive intestinal peptide (VIP).
S6135 Somatostatin 28 ≥97% (HPLC) Mediates inhibition of peptide YY secretion from rat intestinal cultures.
S9313 Somatostatin Fragment 2-9 ≥97% (HPLC), solid  
S9438 Somatostatin Fragment 3-10 ≥96% (HPLC), solid